MBX Biosciences, Inc.·4

Mar 16, 8:02 AM ET

Hawryluk P. Kent 4

4 · MBX Biosciences, Inc. · Filed Mar 16, 2026

Research Summary

AI-generated summary of this filing

Updated

MBX Biosciences CEO P. Kent Hawryluk Buys 18,500 Shares

What Happened
P. Kent Hawryluk, President & CEO and a director of MBX Biosciences (MBX), acquired 18,500 shares in open-market purchases on March 13, 2026. The reported weighted-average price was $28.41 per share, for a total reported transaction value of $525,663. This was a purchase (transaction code P), i.e., the insider added to his holdings.

Key Details

  • Transaction date: 2026-03-13; Form 4 filed: 2026-03-16 (timely filing).
  • Price: weighted average $28.41; trades occurred at prices ranging $28.28–$28.48 (see footnote).
  • Shares acquired: 18,500; total value ≈ $525,663.
  • Shares held after transaction: not specified in the provided extract.
  • Footnotes: F1 notes the weighted-average price and that breakdown by price is available on request; F2 indicates some shares are held by the P. Kent Hawryluk Revocable Trust (he is trustee and disclaims beneficial ownership except to the extent of any pecuniary interest).

Context
This was a direct open-market purchase, which shows the insider bought additional stock; Form 4 rules require filing within two business days after the transaction and this filing appears timely. The footnote about the trust clarifies certain holdings may be held in trust rather than directly in the insider’s name.

Insider Transaction Report

Form 4
Period: 2026-03-13
Hawryluk P. Kent
DirectorPresident & CEO
Transactions
  • Purchase

    Common Stock

    [F1][F2]
    2026-03-13$28.41/sh+18,500$525,663486,777 total(indirect: By Trust)
Holdings
  • Common Stock

    728,274
Footnotes (2)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.28 to $28.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F2]Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Signature
/s/ P. Kent Hawryluk, attorney-in-fact|2026-03-16

Documents

1 file
  • 4
    ownership.xmlPrimary

    4